Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group ...

(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...